Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...

China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

The company has not disclosed pricing or a launch timeline. The approval also comes as Novo Nordisk's Wegovy nears patent expiry later this month, potentially paving the way for lower-cost copycat ...

Pfizer cuts 2026 revenue forecast as COVID sales fade and patents expire. The firm bets on a monthly obesity drug and ...